Table 1.
Characteristics of contrast agents.
| Trade Name | Generic Name | Chemical Structure | Charge | Elimination Way | Risk of NSF * | ACR Classification of GBCA ** |
|---|---|---|---|---|---|---|
| Omniscan ® | Gadodiamide | Linear | Nonionic | Kidney | High | Group I |
| OptiMARK ® | Gadoversetamide | Linear | Nonionic | Kidney | High | Group I |
| Magnevist ® | Gadopentetate dimeglumine | Linear | Ionic | Kidney | High | Group I |
| MultiHance ® | Gadobenate dimeglumine | Linear | Ionic | 97% Kidney 3% Bile |
Medium | Group II |
| Primovist ® | Gadoxetate disodium | Linear | Ionic | 50% Kidney 50% Bile |
Medium | Group III |
| Dotarem ® | Gadoterate meglumine | Cyclic | Ionic | Kidney | Low | Group II |
| ProHance ® | Gadoteridol | Cyclic | Nonionic | Kidney | Low | Group II |
| Gadovist ® | Gadobutrol | Cyclic | Nonionic | Kidney | Low | Group II |
* According to the Committee for Medicinal Products for Human Use (CHMP). ** American College of Radiology Classification (ACR) of gadolinium-based contrast agents relative to risk of nephrogenic systemic fibrosis (NFS).